1. Introduction {#sec1}
===============

The prevalence of gastroesophageal reflux disease (GERD) in the general population has been estimated to be 10--20% \[[@B1]--[@B4]\]. Conversely, most Asian population-based studies have reported a lower prevalence of less than 10% \[[@B3]--[@B6]\]. In epidemiological studies,*H. pylori* and GERD have been found to be negatively associated and strongly related to cytotoxin-associated gene product- (CagA-) positive strains of*H. pylori* \[[@B7]\]. However, an increasing prevalence of GERD and decreasing prevalence of*H. pylori* have been reported in Asian countries \[[@B8]\], which is in agreement with a previous report of no increase in the prevalence of GERD symptoms with age \[[@B4]\]. GERD markedly reduces patients\' quality of life and imparts a significant economic burden on the healthcare system \[[@B9]--[@B11]\]. Therefore, decreasing the prevalence of*H. pylori* infection is an important issue in GERD, especially in Asian populations. In addition,*H. pylori* eradication has been presumed to exacerbate GERD due to improvement of gastritis and the recovery of hypochlorhydria; several studies have been conducted to clarify this controversy.

2. Gastric Acidity and*H. pylori* {#sec2}
=================================

Gastric acid plays a key role in the etiology of GERD and is an element of the disease that may be modified by*H. pylori* infection. Gastric secretion can increase, decrease, or remain steady depending on the pattern of*H. pylori*-related inflammation \[[@B12]\]. The major components of acid secretion in patients with*H. pylori* infection include the density of*H. pylori* colonization, its distribution, and the severity of the mucosal inflammatory response to the infection. Patients with a duodenal ulcer and*H. pylori* infection have antrum-predominant gastritis, which leads to hypergastrinemia and acid hypersecretion. In contrast, patients with gastric ulcer or gastric cancer present mainly with corpus-predominant gastritis or pangastritis, which is characterized by intense destruction or atrophy of acid-secreting glands. Patients who have corpus-predominant gastritis or pangastritis also show gastric acid hyposecretion \[[@B13], [@B14]\]. Bacterial virulence and host inflammatory responses are important in determining patterns of acid secretion and gastritis. East Asian CagA-positive strain of*H. pylori* induces primarily corpus-predominant gastritis or pangastritis with hypochlorhydria. And, East Asian CagA-positive strain is strongly associated with gastric cancer. A Japanese study revealed different sequences of CagA between the regions where gastric cancer is prevalent or not. The authors defined the East Asian CagA-positive strains which showed the specific repeat sequences located in the 3′ region of*cagA* gene. In the study, most CagA-positive strains in Asian countries were East Asian CagA-positive strains and most CagA-positive strains in Western countries were Western CagA-positive strains \[[@B15]\]. In Asian populations with East Asian CagA-positive strains, acid injury may be minimized by hypochlorhydria from pangastritis and gastric atrophy. Additionally, host genetic factors may affect the development of GERD. IL-1B and IL-1RN genetic polymorphisms are inversely associated with the risk of GERD in*H. pylori*-infected subjects because their specific genotypes are linked to corpus atrophy, gastric cancer, and hypochlorhydria \[[@B16]--[@B20]\]. Thus, such specific genotypes, including the IL-1B-511-T, IL-1B-31-C, and IL-1RN-1 alleles, can be considered protective against GERD. In particular, the subjects with IL-1B-511 T allele is accentuated in the presence of*H. pylori* infection due to high gastric mucosal IL-1*β* levels \[[@B20], [@B21]\]. However, other investigators have reported contradictory results that IL-1B-511-T allele was associated with reflux esophagitis \[[@B22]\]. These opposite results suggest ethnic differences regarding IL-1 genetic polymorphisms and levels of gastric mucosal IL-1*β*. Additionally, several genetic risk factors for GERD, including polymorphisms in G-protein beta 3 subunit gene (GNB3) \[[@B23]\], IL-10 \[[@B24]\], CYP2C19 \[[@B25]\], glutathione S-transferase P1 \[[@B26], [@B27]\], cyclin D1 \[[@B28]\], and DNA repair genes \[[@B29]\], may be involved.

The interactions between genetic factors and the virulence of*H. pylori* infection may be the reason for the low prevalence of GERD in Asian countries \[[@B16]--[@B18], [@B20]--[@B22], [@B27], [@B29]\].

3. Epidemiological Evidence of a Link between*H. pylori* Infection and GERD {#sec3}
===========================================================================

[Table 1](#tab1){ref-type="table"} shows recent epidemiological reports of an inverse relationship between*H. pylori* infection and reflux esophagitis or Barrett\'s esophagus in the western countries and East Asian countries \[[@B30]--[@B35]\]. This negative association was also evident in patients with severe GERD and*H. pylori* infection with virulent CagA-positive strains in Western countries \[[@B36], [@B37]\]. The prevalence of*H. pylori* infection is inversely correlated with the risk and severity of reflux esophagitis; \[[@B30], [@B37], [@B38]\] and the prevalence of*H. pylori* infection suggests a protective role in both Barrett\'s esophagus and esophageal adenocarcinoma \[[@B7], [@B34], [@B35], [@B37]--[@B41]\].

4. Proton Pump Inhibitors (PPIs) in GERD Patients with*H. pylori* Infection {#sec4}
===========================================================================

Long-term maintenance therapy of proton pump inhibitors (PPIs) for GERD induces gastritis and progression of gastric atrophy and intestinal metaplasia to gastric adenocarcinoma in patients with*H. pylori* infection \[[@B42], [@B43]\]. These patterns are significantly associated with the CagA-positive strains \[[@B44]\]. Current guidelines, including the Asia-Pacific Consensus for*H. pylori* infection, recommend*H. pylori* eradication in GERD patients requiring long-term PPIs \[[@B45]\]. However, there is no evidence that*H. pylori* eradication reduces the risk of gastric adenocarcinoma in patients with this condition.

5. *H. pylori* Eradication in GERD {#sec5}
==================================

Despite the inverse relationship between*H. pylori* and GERD in cross-sectional studies, the results are less consistent in prospective studies of*H. pylori* eradication in patients with GERD. Early studies revealed that*H. pylori* eradication was positively associated with reflux esophagitis or GERD symptoms in patients with gastric and duodenal ulcer diseases \[[@B46], [@B47]\]. Hiatal hernia, corpus gastritis, and CagA-positive*H. pylori* strains have been reported to be risk factors for newly developed reflux esophagitis after*H. pylori* eradication \[[@B47], [@B48]\]. However, other studies have shown improvement of reflux symptoms after*H. pylori* eradication in patients with peptic ulcer disease and nonulcer dyspepsia \[[@B49], [@B50]\]. The Maastricht IV Consensus Report suggested that*H. pylori* eradication does not exacerbate preexisting GERD or affect treatment efficacy \[[@B51]\]. A recent meta-analysis demonstrated that eradication therapy of*H. pylori* was related to a significantly higher risk of developing*de novo* GERD in Asian studies \[[@B52]\]. In contrast, no such risk has been reported by Western studies \[[@B53]--[@B55]\]. [Table 2](#tab2){ref-type="table"} shows the summaries of the results of meta-analyses. However, this remains an inconclusive issue in Asian countries. For example, two large-scale cohort studies in Korea produced inconsistent results \[[@B56], [@B57]\]. Thus, the revised version of the Korean guidelines for*Helicobacter pylori* infection states that*H. pylori* eradication does not affect the development or clinical course of GERD \[[@B58]\].

6. Conclusion {#sec6}
=============

*H. pylori* infection and GERD are highly prevalent conditions globally. The prevalence of*H. pylori* varies geographically and among ethnicities. Many epidemiological studies have shown a negative correlation between*H. pylori* infection and GERD. A specific virulence factor, such as CagA, and specific host genotypes may affect the diverse prevalence and other aspects of GERD owing to individual differences in acid secretion. A high prevalence of CagA-positive strains has been reported in Asian countries. The diversity of*H. pylori* infection between Western and Asian countries should be considered when analyzing the results of studies of*H. pylori* eradication in GERD patients. To date, cohort studies and randomized controlled trials of the effects of*H. pylori* eradication on GERD are inconclusive. The decreasing prevalence of*H. pylori* and the recovery of acid secretion capacity after eradication in patients with CagA-positive*H. pylori* and corpus gastritis are possible causes of the higher prevalence of GERD in Asian countries. These issues necessitate a more detailed study.
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###### 

Recent epidemiologic studies for association between *H*. *pylori* infection and GERD.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study \[references\]                Type of study     Location    Number of cases in each group (*n*)         *H*. *pylori* infection assessments           *H*. *pylori* prevalence (%) in each group
  ----------------------------------- ----------------- ----------- ------------------------------------------- --------------------------------------------- --------------------------------------------
  Chung et al. 2011 \[[@B30]\]        Case-control      Korea       Reflux esophagitis (2,808)  \               Serology                                      Reflux esophagitis (38.4)  \
                                                                    Control (2,808)                                                                           Control (58.2)

                                                                                                                                                              

  Gunji et al. 2011 \[[@B31]\]        Cross-sectional   Japan       Erosive esophagitis (1,831)  \              Serology                                      Erosive esophagitis (13.6)  \
                                                                    No erosive esophagitis (8,009)                                                            No erosive esophagitis (33.4)

                                                                                                                                                              

  Chiba et al. 2012 \[[@B32]\]        Cross-sectional   Japan       Erosive esophagitis (728)  \                Serology                                      Erosive esophagitis (9.4)  \
                                                                    No erosive esophagitis (4,262)                                                            No erosive esophagitis (14.9)

                                                                                                                                                              

  Ashktorab et al. 2012 \[[@B33]\]    Case-control      USA         Reflux esophagitis (58)  \                  Biopsy silver stain or immunohistochemistry   Reflux esophagitis (3.8)  \
                                                                    Gastritis (1,558)  \                                                                      Gastritis (40)  \
                                                                    Reflux esophagitis and gastritis (363)  \                                                 Reflux esophagitis and gastritis (34)  \
                                                                    Normal control (41)                                                                       Normal control (34)

                                                                                                                                                              

  Sonnenberg et al. 2010 \[[@B34]\]   Cross-sectional   USA         Barrett\'s esophagus (2,510)  \             Biopsy immunohistochemistry                   Barrett\'s esophagus (5.7)  \
                                                                    No Barrett\'s esophagus (76,475)                                                          No Barrett\'s esophagus (12.2)

                                                                                                                                                              

  Thrift et al. 2012 \[[@B35]\]       Case-control      Australia   Simple Barrett\'s esophagus (217)  \        Serology                                      Simple Barrett\'s esophagus (12)  \
                                                                    Dysplastic Barrett\'s esophagus (95)  \                                                   Dysplastic Barrett\'s esophagus (3)  \
                                                                    Control (398)                                                                             Control (18)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GERD: gastroesophageal reflux disease.

###### 

Results of meta-analyses for *Helicobacter pylori* eradication on GERD.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study \[references\]              Number of enrolled studies    Location of enrolled studies   Risk ratio (95% confidence interval)                                             Conclusion
  --------------------------------- ----------------------------- ------------------------------ -------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------
  Xie et al. 2013 \[[@B52]\]        12 cohort studies and\        *Cohort*  \                    3 type A cohort studies: 2.50 (1.46--4.26, *P* = 0.0008)  \                      Eradication of the infection may be a risk factor for *de novo* endoscopic GERD, especially in Asian populations.
                                    12 RCTs                       Europe: 4  \                   9 type B cohort studies: 1.70 (1.30--2.23, *P* = 0.0001)  \                      
                                                                  North America: 1  \            12 RCTs: 1.09 (1.23--3.22, *P* = 0.005)  \                                       
                                                                  Asia: 7  \                     4 Asian RCTs: 4.53 (1.66--12.36, *P* = 0.003)                                    
                                                                  *RCTs*  \                                                                                                       
                                                                  Europe: 7  \                                                                                                    
                                                                  South America: 1  \                                                                                             
                                                                  Asia: 4                                                                                                         

                                                                                                                                                                                  

  Yaghoobi et al. 2010 \[[@B53]\]   5 cohort studies and 7 RCTs   *Cohort*  \                    5 cohort studies: 1.37 (0.89--2.12, *P* = 0.15)  \                               There is no association between *H*. *pylori* eradication and development of new cases of GERD in the population of dyspeptic patients.
                                                                  Europe: 1  \                   6 RCTs using erosive GERD as outcome: 1.11 (0.81--1.53, *P* = 0.52)  \           
                                                                  Asia: 4  \                     5 RCTs using symptomatic GERD as outcome: 1.22 (0.89--1.69, *P* = 0.22)          
                                                                  *RCTs*  \                                                                                                       
                                                                  Europe: 3  \                                                                                                    
                                                                  North America: 3  \                                                                                             
                                                                  South America: 1                                                                                                

                                                                                                                                                                                  

  Qian et al. 2011 \[[@B54]\]       11 RCTs                       Europe: 5  \                   7 RCTs using heartburn symptom as outcome: 0.88 (0.63--1.23, *P* = 0.46)  \      *H*. *pylori* eradication does not aggravate the clinical outcomes in  \
                                                                  North America: 3  \            10 RCTs using erosive esophagitis as outcome: 0.97 (0.67--1.40, *P* = 0.88)      terms of short-term and long-term posteradication occurrence of GERD.
                                                                  South America: 1  \                                                                                             
                                                                  Asia: 1  \                                                                                                      
                                                                  Multinational: 1                                                                                                

                                                                                                                                                                                  

  Saad et al. 2012 \[[@B55]\]       10 RCTs                       Europe: 7  \                   10 RCTs using symptomatic GERD as outcome: 0.81 (0.56--1.71, *P* = 0.27)  \      Treatment of *H*. *pylori* does not seem to increase GERD symptoms or reflux esophagitis.  \
                                                                  North America: 2  \            10 RCTs using endoscopic esophagitis as outcome: 1.13 (0.72--1.78, *P* = 0.59)   However, documented eradication of *H*. *pylori* appears to significantly improve GERD symptoms.
                                                                  Asia: 1                                                                                                         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RCT: randomized controlled trial; GERD: gastroesophageal reflux disease; *H*. *pylori*: *Helicobacter pylori*.
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